Neil Woodford has just bought Lloyds Banking Group plc and sold GlaxoSmithKline plc

Here’s why Neil Woodford has backed Lloyds Banking Group plc (LON:LLOY) and dumped GlaxoSmithKline plc (LON:GSK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There’s stunning news to end the week in the investing world. Fund manager and long-time uber-bear on banks Neil Woodford has just revealed he’s bought a significant stake in Lloyds (LSE: LLOY) for his flagship equity income fund.

Perhaps just as surprising for Woodford-watchers, he’s also announced that he’s completely disposed of his holding in old favourite GlaxoSmithKline (LSE: GSK).

Contrarian opportunity

Woodford’s update shows Lloyds as representing 2.05% of his equity income fund (as of 30 April), ranking it as the 11th-largest holding in his 131-strong portfolio. The purchase is his most notable in what is a veritable sea of trades over recent weeks. What’s behind them?

In short, his communications chief explains: “Neil has been keen to take advantage of what he sees as a compelling, contrarian opportunity in domestic stocks, which have become too cheap to ignore in the wake of the Brexit vote last year”.

Black Horse set to gallop

Woodford reckons investors have become “far too pessimistic about the UK economy”, particularly about inflation and the business and consumer confidence environment leading up to the Brexit impact date in 2019.

He points to record levels of employment and job vacancies but also, crucially, says “the one other very big significant factor which I’ve been waiting for for some time is that the credit environment has begun to normalise in the UK”. He believes banks are now “broadly repaired” and that lending dynamics are providing a positive for the economy for “the first time really since the financial crisis”.

As such, he’s turned bullish on the outlook for domestic banking. Specifically, he and his team “view Lloyds as a well-managed bank with a conservative approach to its balance sheet. Its valuation looks very attractive in our view, and it has the ability to pay a very healthy and growing level of dividend”.

Lloyds’ attractive valuation is something many of us here at the Fool have been highlighting. The forward price-to-earnings ratio is a bargain basement 9.5, while the consensus forecast dividend gives a glorious yield of 5.4%, rising to 6.2% next year. Like Woodford, I believe the shares are very buyable at their current level of less than 70p.

Domestic cyclicals

Woodford’s optimism on the UK economy hasn’t just led him to buy Lloyds. He’s pumped cash into a fair number of carefully selected “domestic cyclicals”. His update lists brick-maker Forterra and student accommodation specialist Watkin Jones, as well as more familiar names, including Barratt Developments, Taylor Wimpey, British Land, Topps Tiles and Card Factory.

End of an era

The complete disposal of FTSE 100 pharma giant GlaxoSmithKline (after holding it for 15 years) is the most notable trade Woodford’s made to fund his new stock purchases. He hasn’t soured on the sector generally — AstraZeneca remains his biggest holding — but he’s tired of what he sees as Glaxo’s “sub-optimal business strategy”.

He’s long called for a break-up of the group to unlock shareholder value, but with new chief executive Emma Walmsley having got the gig as a ‘continuity candidate’, he reckons “the prospect of a Glaxo break-up now looks more remote than ever”.

His base assumption is that under a continuing sub-optimal conglomerate structure, “shareholders face a cut to the dividend”. I’m not altogether convinced by Woodford’s argument but it’s certainly something for shareholders or prospective investors to consider.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca and Lloyds Banking Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »